Part D Enrollees Who Take Specialty Drugs Will See Out-of-Pocket Costs Rise in 2016

December 2, 2015
Contact: John Rother
Email: [email protected]

A new Kaiser Family Foundation analysis released today shows that in 2016, Medicare Part D enrollees will face thousands of dollars in out-of-pocket costs for specialty medications treating cancer, rheumatoid arthritis, multiple sclerosis and hepatitis C.

In response to the findings, John Rother, executive director of the Campaign for Sustainable Rx Pricing, issued the following statement:

“This latest analysis from the Kaiser Family Foundation paints a troubling picture for the future of the Medicare Part D program and beneficiaries who rely on access to affordable treatments. As the analysis points out, Part D enrollees will need to dig deep into their pockets in 2016 as a result of unprecedented price increases on already exorbitantly priced specialty drugs. Our system is out of balance and simply cannot sustain this current trend in drug pricing. We are on a dangerous path and our country desperately needs and deserves a responsible, market-based pricing solution before it’s too late.”

To find out more information about the Campaign for Sustainable Rx Pricing, visit


Sign-up for updates

  • This field is for validation purposes and should be left unchanged.